Osteoporosis in men: recent progress (Q38077109)

28 August 2017

1 reference

title

Osteoporosis in men: recent progress (English)

1 reference

28 August 2017

0 references

Robert A Adler

1

1 reference

28 August 2017

publication date

25 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

44

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

40-46

1 reference

Estimation of the lifetime risk of hip fracture for women and men in Canada.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Hip fracture-associated mortality reconsidered.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Glucocorticoid-induced osteoporosis in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Survival following primary androgen deprivation therapy among men with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Involutional osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Osteoporosis in men: insights for the clinician

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

The effects of a FRAX revision for the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Development of a nomogram for individualizing hip fracture risk in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Osteoporosis in men: the value of laboratory testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Secondary osteoporosis in men and women: clinical challenge of an unresolved issue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Idiopathic hypercalciuria and bone health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Fracture risk associated with the use of morphine and opiates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

The decline of androgen levels in elderly men and its clinical and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Osteoblast differentiation influences androgen and estrogen receptor-alpha and -beta expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Aromatase activity and bone loss in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

BMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Laboratory testing for secondary osteoporosis evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Vertebral fractures in males with prolactinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

High prevalence of radiological vertebral fractures in HIV-infected males.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Bone mineral density and fractures in older men with chronic obstructive pulmonary disease or asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Drug-induced osteoporosis: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Predictors of Non-Spine Fracture in Elderly Men: The MrOS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Official Positions for FRAX® clinical regarding international differences from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Normocalcemic primary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Towards a diagnostic and therapeutic consensus in male osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Osteoporosis in men: what has changed?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

New understanding and treatments for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Efficacy and safety of monthly ibandronate in men with low bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Fracture risk and zoledronic acid therapy in men with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Skeletal and extraskeletal actions of denosumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Therapy of osteoporosis in men with teriparatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Osteoporosis in men: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Long-term use of bisphosphonates in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Epidemiology of fractures in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

The near absence of osteoporosis treatment in older men with fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Oral corticosteroids and fracture risk: relationship to daily and cumulative doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Hypovitaminosis D and Bone Mineral Metabolism and Bone Density in Hyperthyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-013-9880-7

Relationship of serum sex steroid levels to longitudinal changes in bone density in young versus elderly men.

21 January 2018

1 reference

12 December 2020

Forearm bone mineral density in familial hypocalciuric hypercalcemia and primary hyperparathyroidism: a comparative study

1 reference

12 December 2020

Efficacy of strontium ranelate on bone mineral density in men with osteoporosis

1 reference

12 December 2020

Do men and women fracture bones at similar bone densities?

1 reference

12 December 2020

Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence?

1 reference

12 December 2020

A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and

1 reference

12 December 2020

Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.

1 reference

12 December 2020

The diagnosis of osteoporosis

1 reference

12 December 2020

Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs

1 reference

12 December 2020

Risk of Subsequent Fracture After Low-Trauma Fracture in Men and Women

1 reference

12 December 2020

Risk of fracture after androgen deprivation for prostate cancer

1 reference

12 December 2020

Secondary causes of osteoporosis

1 reference

12 December 2020

10.1007/S12020-013-9880-7

Identifiers

DOI

1 reference

28 August 2017

1 reference